Irbesartan Jubilant

Irbesartan, the active ingredient in Irbesartan Jubilant, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to lower high blood pressure and to protect kidney function in patients with diabetes‑related kidney disease. The medication works by blocking the effects of angiotensin II, a hormone that narrows blood vessels, thereby helping to relax and widen the vessels.

GNH USA supplies Irbesartan Jubilant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is used to treat conditions related to the renin‑angiotensin system, primarily hypertension and diabetic kidney disease.

Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Left ventricular hypertrophy: lowers risk of stroke and cardiovascular events in hypertensive patients with LVH.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain often improving with continued therapy. - Fatigue: feeling unusually tired or weak. - Upper respiratory tract infection: nasopharyngitis or mild cough.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or throat requiring immediate medical attention. - Hyperkalemia: elevated blood potassium that can cause cardiac arrhythmia. - Acute renal failure: sudden decline in kidney function, especially with concomitant nephrotoxic drugs. - Hepatic injury: signs of liver dysfunction such as jaundice or elevated transaminases.

When prescribing Irbesartan, clinicians should consider several safety measures to minimize risks.

Blood pressure monitoring: check regularly to avoid hypotension. Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. Electrolyte surveillance: monitor serum potassium, especially if combined with potassium‑sparing agents. Pregnancy avoidance: contraindicated in pregnancy due to risk of fetal toxicity. Hepatic impairment: use with caution in patients with severe liver disease. Store at below 25°C: keep in the original container, protect from moisture and light.

Irbesartan can interact with several medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Aliskiren (in diabetes): combined use may increase renal dysfunction and hyperkalemia. - Dual ARB/ACE inhibitor therapy: heightened risk of hypotension, renal impairment and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - High‑dose NSAIDs: can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance blood‑pressure lowering, requiring dose adjustment. - Lithium: increased lithium concentrations, necessitating serum level monitoring. - Cyclosporine: may raise serum creatinine, so renal function should be checked regularly.